Exciting phase 3 trials data in metastatic #ProstateCancer @myESMO #ESMO26 #ESMOAmbassadors #PEACE1 #Capitello281 @Silke_Gillessen @neerajaiims @OncoAlert @OncBrothers @PCFnews @shilpaonc @EAntonarakis @Parminder1699 @Uromigos @montypal @docjavip @drenriquegrande @cdanicas
270 浏览 · 10 赞 · 3 转发 · 0 回复
Neoadjuvant toripalimab combined with chemotherapy for locally advanced penile squamous cell carcinoma: A multicenter prospective, single-arm, phase II clinical trial
https://esmocongress.esmo.orgSafety and efficacy of ixotatug vedotin (TORL-1-23), a claudin 6-targeted ADC, as monotherapy in germ cell tumors (GCT)
https://esmocongress.esmo.orgUpdated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.orgDistinguishing clonal hematopoiesis (CH) from tumor homologous recombination repair (HRR) alterations in liquid biopsy: Implications for PARP inhibitor (PARPi) use in metastatic castration-resistant prostate cancer (mCRPC)
https://esmocongress.esmo.orgUtility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.orgPlasma ctDNA as standalone or adjunct to tumour tissue for HRR and PI3K/AKT genotyping in mCRPC: PROMPT (NCT04746300)
https://esmocongress.esmo.org#ESMO26: Adding capivasertib to abiraterone and adding abiraterone to standard care resulted in significant improvements in #ProstateCancer in the phase III CAPItello-281 and PEACE-1 #ClinicalTrials, as discussed by Elena Castro 🔗 https://ow.ly/k8xU50ZZk08 #InsightsbyESMO在 X 查看被引用的帖子
来源:Petros Grivas · x.com
